Karyopharm to Participate in Upcoming Investor Conferences

NEWTON, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company's management team will participate in the following upcoming investor conferences:

- The Bank of America Merrill Lynch Health Care Conference 2019 on Wednesday, May 15, 2019.
- The 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019, and will present at 2:05 p.m. ET.

A live webcast of the RBC presentation can be accessed on the "Events & Presentations" page in the Investors section of the Company's website, http://investors.karyopharm.com/events-presentations. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

Contacts:

Investors:
Karyopharm Therapeutics Inc.
Ian Karp
Vice President, Investor and Public Relations
857-297-2241 | ikarp@karyopharm.com

Media: Argot Partners David Rosen

212-600-1902 | david.rosen@argotpartners.com

Source: Karyopharm Therapeutics Inc.

Karyopharm